Mr. Lucas Zimmerman reports

BIOHARVEST SCIENCES ANNOUNCES CONVERSION OF DEBT NOTES

Bioharvest Sciences Inc. has completed an early conversion of convertible debt notes, associated with the convertible debt financing rounds completed on October, November, 2022, and July, October, December, 2023.

Bioharvest reports that a total of $5,675,059.91 (Canadian) (principal loans plus accrued interest) has been converted into 22,826,132 common shares. As part of the term of October and December, 2023, convertible loans, the company issued 3,090,284 early exercise warrants at 22.2 U.S. cents for early conversion. Two million nine hundred seventeen thousand nine hundred eighty-seven early exercise warrants will expire on Oct. 30, 2025, and 172,297 will expire on Dec. 22, 2025.

Terms of the convertible notes

For the terms of the convertible notes, please refer to news releases issued in October and November, 2022, in July, 2023, and in October and December, 2023.

About Bioharvest Sciences Inc.

Bioharvest is a leader in botanical synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. Bioharvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals: as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules; and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements.

We seek Safe Harbor.